ROCKET PHARMACEUTICALS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
350 FIFTH AVENUE, NEW YORK, NY, 10118
Mailing Address
350 FIFTH AVENUE, NEW YORK, NY, 10118
Phone
646-440-9100
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$527.70M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 10-K Annual financial report | February 26, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
Annual Reports
10-K
February 26, 2026
- Leading gene therapy company focused on ultra-rare genetic diseases with significant unmet medical needs.
- LAD-I (RP-L201) program is in a pivotal Phase 2 study with promising interim data and special FDA designations, targeting regulatory submission in late 2026 or early 2027.
Insider Trading
SELL
4 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.